Literature DB >> 17087178

Cancer Care Ontario's computerized physician order entry system: a province-wide patient safety innovation.

Anna Greenberg1, Sarah Kramer, Vickie Welch, Emily O'Sullivan, Stephen Hall.   

Abstract

More than one-third of all women and men in Canada will develop cancer during their lifetimes. Cancer patients typically require complex chemotherapy regimens, specific to their type and stage of disease, to slow or stop cancer cells from growing, multiplying, or spreading to other parts of the body. Despite the complexity of managing medication regimens for cancer patients and the associated risks to patient safety, current medical oncology practice throughout most of Canada is still to use paper-based tools, policies and procedures. To increase patient safety by reducing prescription errors and to offer clinical decision support to medical oncologists across the province, Cancer Care Ontario (CCO) developed and implemented Canada's first, cancer-specific computerized physician order entry (CPOE) system. This e-health innovation is currently in use in 11 cancer centres, and represents the largest ambulatory oncology CPOE implementation in Canada, with a 100% implementation success rate, and greater than 90% physician adoption. This paper describes the critical success factors in the design and implementation of CCO's CPOE system, including Web-based training and ease of administration to maximize physician adoption, incorporating point-of-care access to clinical practice guidelines into the tool, and the use of CPOE data to monitor and increase access to anti-cancer drugs and patient safety.

Entities:  

Mesh:

Year:  2006        PMID: 17087178     DOI: 10.12927/hcq.2006.18468

Source DB:  PubMed          Journal:  Healthc Q        ISSN: 1710-2774


  9 in total

1.  Implementation of safeguards to improve patient safety in chemotherapy.

Authors:  M J Huertas-Fernández; Mª J Martínez-Bautista; M E Rodríguez-Mateos; M Zarzuela-Ramírez; T Muñoz-Lucero; J M Baena-Cañada
Journal:  Clin Transl Oncol       Date:  2017-03-30       Impact factor: 3.405

2.  Improving electronic oral chemotherapy prescription: can we build a safer system?

Authors:  Saul N Weingart; Thea Mattsson; Junya Zhu; Lawrence N Shulman; Michael Hassett
Journal:  J Oncol Pract       Date:  2012-09-25       Impact factor: 3.840

Review 3.  Computerized prescriber order entry in the outpatient oncology setting: from evidence to meaningful use.

Authors:  V Kukreti; R Cosby; A Cheung; S Lankshear
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

4.  Computerized prescriber order entry implementation in a physician assistant-managed hematology and oncology inpatient service: effects on workflow and task switching.

Authors:  David A Hanauer; Kai Zheng; Elaine L Commiskey; Mary G Duck; Sung W Choi; Douglas W Blayney
Journal:  J Oncol Pract       Date:  2012-11-13       Impact factor: 3.840

5.  Characteristics of medication errors with parenteral cytotoxic drugs.

Authors:  A Fyhr; R Akselsson
Journal:  Eur J Cancer Care (Engl)       Date:  2012-02-16       Impact factor: 2.520

6.  Uptake of a web-based oncology protocol system: how do cancer clinicians use eviQ cancer treatments online?

Authors:  Julia M Langton; Nicole Pesa; Shelley Rushton; Robyn L Ward; Sallie-Anne Pearson
Journal:  BMC Cancer       Date:  2013-03-12       Impact factor: 4.430

Review 7.  Minimising treatment-associated risks in systemic cancer therapy.

Authors:  Ulrich Jaehde; Andrea Liekweg; Sven Simons; Martina Westfeld
Journal:  Pharm World Sci       Date:  2007-09-29

8.  From a reactive to a proactive safety approach. Analysis of medication errors in chemotherapy using general failure types.

Authors:  A Fyhr; S Ternov; Å Ek
Journal:  Eur J Cancer Care (Engl)       Date:  2015-08-04       Impact factor: 2.520

9.  Factors Determining the Success and Failure of eHealth Interventions: Systematic Review of the Literature.

Authors:  Conceição Granja; Wouter Janssen; Monika Alise Johansen
Journal:  J Med Internet Res       Date:  2018-05-01       Impact factor: 5.428

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.